Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04493619 · ClinicalTrials.gov registry record · Phase 1
PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
A Phase 1 study, sponsored by Opna Bio.
- Terminated
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT04493619 is a Phase 1 study that was terminated before completion, run by Opna Bio. The registered enrollment target is 37 participants.
The verdict
NCT04493619, a Phase 1 study, was terminated before completion, sponsored by Opna Bio.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in Advanced Gynecological Malignancies with a Known ARID1A Mutation and PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer.
Interventions
- DRUG Carboplatin
- DRUG PLX2853
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2020-08-11 |
| Est. Completion | 2022-04-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04493619
The ClinicalTrials.gov registry entry for NCT04493619 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Opna Bio, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT04493619 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04493619 about?
NCT04493619 is a clinical study titled "PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer". The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in Advanced Gynecological Malignancies with a Known ARID1A Mutation and PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial O...
What is the current status of trial NCT04493619?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2020-08-11. Estimated completion is 2022-04-25.
What interventions are being tested in trial NCT04493619?
The interventions under investigation include: Carboplatin (DRUG), PLX2853 (DRUG).
Who is sponsoring clinical trial NCT04493619?
This trial is sponsored by Opna Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.